Founded by a group of senior research and management elites from the global pharmaceutical industry in 2004, Sundia MediTech Co., Ltd. is a Shanghai-based contract research organization (CRO) providing excellent and efficient “one-stop” new drug R&D and production services to global pharmaceutical enterprises and biotechnology companies.
Since its founding 12 years ago, Sundia has continued to expand its scale, and developed the laboratory area from the original 500m2 to the present 23,000m2, with first-class research and production facilities.
In 2008, Sundia Company ranked 52nd among Deloitte Asia Pacific Technology Fast 500™ Rankings and 16th among Deloitte Technology Fast 50 China owing to its 928% financial growth, and it was rated as one of the “China top 50 most valuable companies for investment” for two consecutive years by a top VC. Sundia also won titles such as China’s “High-tech Enterprise”, “Shanghai Key Service Outsourcing Enterprise”, “Pudong New Area Institution of Enterprise Technical Development”, “Red Herring Top 100 Asia Winner”, “2009 China Top 100 Growing Service Outsourcing Enterprises”, and in January 2011 “Enterprise of the Year in Innovative Zhangjiang · Glorious Pharma Valley”.
Company Strength
The company has world-class expertise in organic synthesis, medicinal chemistry, combinatorial library, hit compound generation, lead optimization, process chemistry R&D, APIs manufacturing under cGMP, preparation development, pharmacological research, in vitro & in vivo pharmacokinetics (PK), and preclinical studies, etc., and has established a batch of professional laboratories with international advanced level and meeting GMP requirements such as efficient API laboratory, analytical laboratory, and drug stability laboratory. Over the past 12 years, Sundia has carried out comprehensive R&D cooperation with over 200 Chinese and overseas pharmaceutical companies, colleges and universities, and institutes, etc. through self-built new drug R&D platform, discovered more than a dozen different candidate drugs, and undertaken over 30 innovative drug preclinical R&D projects, wherein, more than 20 have entered the clinical study stage, and 2 have progressed to clinical trial Phase II.
The company has created characteristics in the high-end CRO services provided in the field of new drug discovery, and discovered more than a dozen candidate drugs for customer enterprises. In the new drug discovery and R&D services provided to the U.S. Xcovery Company, the company discovered 4 candidate drugs in two years and a half at a cost dozens of times lower than the international level, with the first clinical trial approval received in 2009, and its mode was rated as “absolutely the most efficient and economic new drug R&D mode” by the customer.
Development History
May 2004
► Sundia was founded
2005 ~ 2008
► It initiated the first new drug development project
► It was one of the first CRO companies receiving the U.S. FDA new drug IND approval in China
► It received the first CFDA new drug IND approval
2009 ~ 2012
► Its API GMP kilo lab successfully passed the audit of the first U.S. pharmaceutical enterprise
► It established the oncology and nervous system pharmacology service platform
► Its animal laboratory successfully passed the audit of the first EU pharmaceutical enterprise
► It passed ISO 9001 certification
► Its subsidiary Hebei Sundia Meditech Company Ltd. was formally put into operation
► It won the honor of Deloitte Asia Pacific Technology Fast 500™ Rankings for five consecutive years
► Its 2 drugs entered clinical study
► Its Taicang manufacturing base was put into operation
► It won “2016 Member Unit with Outstanding Contributions of Shanghai Pudong Modern Service Industry Promotion Association”<...
(All Rights Reserved)